Deletion of pancreas-specific miR-216a reduces beta-cell mass and inhibits pancreatic cancer progression in mice
Süheda Erener, Cara E. Ellis, Adam Ramzy, Maria M. Glavas, Shannon O’Dwyer, Sandra Pereira, Tom Wang, Janice Pang, Jennifer E. Bruin, Michael Riedel, Robert K. Baker, Travis D. Webber, Marina Lesina, Matthias Blüher, Hana Algül, Janel L. Kopp, Stephan Herzig, Timothy J. Kieffer
Abstract
reduces the propensity of pancreatic cancer precursor lesions. Notably, circulating miR-216a levels are elevated in both mice and humans with pancreatic cancer. Collectively, our study gives insights into how β-cell mass and acinar cell growth are modulated by a pancreas-specific miRNA and also suggests miR-216a as a potential biomarker for diagnosis of pancreatic diseases.
Topics & Concepts
Pancreatic cancerPancreasCancer researchIsletDownregulation and upregulationmicroRNABeta cellBiologyCell growthEndocrinologyCancerCellInternal medicineChemistryMedicineInsulinBiochemistryGenePancreatic function and diabetesPancreatic and Hepatic Oncology ResearchMicroRNA in disease regulation